![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Synairgen’s Inhaled COVID-19 Treatment Found to Reduce Risk of Severe Disease
Synairgen’s Inhaled COVID-19 Treatment Found to Reduce Risk of Severe Disease
Synairgen has released the results of a phase 2 clinical trial in which its inhaled interferon beta demonstrated benefit in hospitalized COVID-19 patients.
The trial of 101 patients found that SNG001 reduced the risk of developing severe disease by 79 percent compared to a placebo. People given the treatment were also more than twice as likely to recover over the course of treatment than those given a placebo.
There were no deaths among patients given SNG001 compared to three among those given a placebo.
Upcoming Events
-
21Oct